Remdesivir
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Remdesivir: From COVID-19 to Multiple Endocrine Neoplasia
One-Sentence Summary
Remdesivir is an intravenous antiviral (RNA-dependent RNA polymerase inhibitor) established for COVID-19 treatment, and it is not currently marketed in Denmark. The TxGNN model’s top-ranked prediction is Multiple Endocrine Neoplasia (score 99.50%), but this candidate has zero supporting clinical trials or publications, and the evidence pack’s own mechanistic review flags it as a likely false-positive with no biological plausibility.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | COVID-19 (per clinical trial records in this evidence pack, e.g. NCT04669990: “Remdesivir has recently received full approval for COVID-19 by US FDA”); not independently confirmed via Danish regulatory filings, as the drug is not marketed in Denmark |
| Predicted New Indication | Multiple Endocrine Neoplasia |
| TxGNN Prediction Score | 99.50% |
| Evidence Level | L5 |
| Denmark Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the structured drug.original_moa field (flagged as a Blocking/High-severity data gap in this pack). However, the evidence pack’s own rationale text describes Remdesivir as a nucleotide analog prodrug that targets RNA-dependent RNA polymerase (RdRp), giving it activity against (+)ssRNA viruses such as SARS-CoV-2 and Ebola.
Multiple Endocrine Neoplasia (MEN) is a hereditary endocrine tumour syndrome driven by RET or MEN1 gene mutations — a genetic oncogenic pathway with no known connection to viral RdRp inhibition. The evidence pack explicitly characterizes this pairing as a “typical TxGNN false-positive high-score candidate”: the model score is high, but there is no supporting biological rationale, and querying ClinicalTrials.gov, ICTRP, and PubMed for this drug-disease pair returned zero results across all three sources.
It is also worth noting that the next-ranked candidate in this pack, “HIV infectious disease” (score 99.32%), superficially appears better supported — 23 registered trials and 20 publications. On review, however, every cited trial and abstract concerns COVID-19/SARS-CoV-2 (e.g. the WHO Solidarity Trial, ACTT-3, ACTIV-3/TICO), not HIV. Remdesivir’s RdRp-targeting mechanism does not apply to HIV, a retrovirus that depends on reverse transcriptase. This strongly suggests a disease-ontology mapping error in the pipeline rather than genuine anti-HIV evidence, and should not be read as supporting this repurposing direction either.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Not marketed in Denmark — no marketing authorisations are on file (total_licenses = 0).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Key warnings, contraindications, and drug-drug interaction data were not available in this evidence pack (DG001, Blocking severity — data must be retrieved from the official product label before this candidate can enter any safety screening stage).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (Multiple Endocrine Neoplasia) has no supporting clinical trials or literature and no plausible mechanistic link to Remdesivir’s antiviral mode of action. The apparently better-evidenced alternative (HIV infectious disease) is undermined by a likely disease-label mismatch — all associated trials and papers are COVID-19 studies, not HIV studies.
To proceed, the following is needed:
- Correct the disease-ontology mapping for the “HIV infectious disease” candidate (evidence appears to be COVID-19 data mislabeled)
- Resolve DG001 (Blocking): obtain TFDA/Danish SmPC warnings, contraindications, and DDI data before any S1 safety screening
- Resolve DG002 (High): obtain confirmed original MOA from the DrugBank API
- Verify Denmark/EU marketing status directly (EMA centralised authorisation for Veklury exists globally; this pack shows 0 licenses, which should be reconciled)
- De-duplicate the ranked candidate list — ranks 1–2, 3–4, 5–6, 7–8, and 9–10 are each identical repeated entries — before any re-scoring or prioritization
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.